过氧化物酶体增殖物激活受体γ激动剂在高血压心血管重塑中的作用机制

摘要
图/表
参考文献
相关文章 (12)

［1］ Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions[J].Mutat Res，2000，448(2):121-138.

［2］ Zhang L, Xie P, Wang J, et al.Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension[J]. J Biol Chem，2010，285(18):13666-13677.

［3］ Meredith D, Panchatcharam M, Miriyala S,et al.Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling[J]. Arterioscler Thromb Vasc Biol，2009,29(4):465-471.

［4］ NuezAnita RE, CajeroJuárez M, Aceves C. Peroxisome proliferator-activated receptors：role of isoform gamma in the antineoplastic effect of iodine in mammary cancer[J]. Curr Cancer Drug Targets, 2011 ,11(7):775-786.

［5］ Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear receptor PPARgamma[J]. J Diabetes Complications，2002，16(1):46-49.

［6］ Flori E, Mastrofrancesco A, Kovacs D, et al. 2,4,6-Octatrienoic acid is a novel promoter of melanogenesis and antioxidant defence in normal human melanocytes via PPAR-γ activation[J]. Pigment Cell Melanoma Res，2011，24(4):618-630.

［7］ Deng T, Sieglaff DH, Zhang A, et al. A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function[J]. J Biol Chem，2011,286(35):3072330731.

［8］ Hashimoto R, Umemoto S, Guo F, et al. Nifedipine activates PPARgamma and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP[J]. J Atheroscler Thromb，2010,17(8):785-795.

［9］ De Ciuceis C，Amiri F，Iglarz M, et al.Synergistic vascular protective effects of combinedlow doses of PPARa and PPARc activators inangiotensin II-induced hypertension in rats[J]. Br J Pharmacol，2007,151(1):45-53.

［10］ Sugawara A, Uruno A, Kudo M, et al. PPARγ agonist beyond glucose lowering effect[J]. Korean J Intern Med，2011,26(1):19-24.

［11］　 Kim KY, Ahn JH, Cheon HG. Antiangiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation[J]. Mol Cell Biochem，2011,358(1/2):375-385.

［12］　 Kulkarni AA, Thatcher TH, Olsen KC, et al. PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis[J]. PLoS One，2011,6(1): e15909.

［13］　 Gong K, Chen YF, Li P, et al. Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice[J]. J Hypertens，2011,29(9):1810-1819.

［14］　 Schiffrin EL. Immune modulation of resistance artery remodelling[J]. Basic Clin Pharmacol Toxicol，2012,110(1):70-72.

［15］　Chen NG, Han X.Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium［Ｊ］. Biochem Biophys Res Commun, 2001,282(3):717-722.

［16］　 Gao M, Hu Z, Zheng Y, et al. Peroxisome proliferatoractivated receptor　γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor　κB and activator protein 1[J]. Shock，　2011,36(3):228-234.

［17］ Choi JS, Bae JY, Kim DS, et al. Dietary compound quercitrin dampens VEGF induction and PPARgamma activation in oxidized LDL-exposed murine macrophages: association with scavenger receptor CD36[J]. J Agric Food Chem，2010,58(2):1333-1341.

［18］ Heltianu C, Robciuc A, Botez G, et al. Modified low density lipoproteins decrease the activity and expression of lysosomal Acid lipase in human endothelial and smooth muscle cells\[J\].Cell　Biochem　Biophys，2011,61(1):209-216.

［19］　 Soskic＇ SS, Dobutovic＇ BD, Sudar EM,et al. Regulation of inducible nitric oxide synthase(iNOS) and its potential role in insulin resistance, diabetes and heart failure[J].Open Cardiovasc Med J, 2011, 5, 153-163 .

［20］ Hamblin M, Chang L, Fan Y，et al. PPARs and the cardiovascular system［J］. Antioxid Redox Signal，2009，11(6):1415-52.

［21］ Game BA, Maldonado A, He L, et al.Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism[J]. Atherosclerosis，2005,178(2):249-256.

［22］ Hui X, Lam KS, Vanhoutte PM, et al. Adiponectin and cardiovascular health: an update[J]. Br J Pharmacol，2012 ,165(3):574-590.

［23］ Dubuisson O, Dhurandhar EJ, Krishnapuram R, et al. PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells[J]. Endocrinology，2011,152(10):3648-3660.

［24］ Woodard GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology[J]. Int Rev Cell Mol Biol，2008,268:59-93.

［25］ Nisbet RE, Bland JM, Kleinhenz DJ，et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model[J]. Am J Respir Cell Mol Biol，2010,42(4):482-490.

［26］　 Zhao SM, Shen LH, Li HW, et al.Down-regulation of the expression of angiotensin II type 1 receptor in neonatal rat cardiac fibroblast by activation of PPARgamma signal pathway[J]. Chin J Physiol，2008,51(6):357-362.

［27］ Su XL, Dong HR, Yan MR, et al.Association between peroxisome proliferator-activated receptor gamma coactivator-1 alpha polymorphism and hypertension in Mongolians in Inner Mongolia[J]. Genet Mol Res，2011, 10(4):3930-3936.

［28］ Caniffi C, Elesgaray R, Gironacci M, et al. C-type natriuretic peptide effects on cardiovascular nitric oxide system in spontaneously hypertensive rats[J]. Peptides，2010 ,31(7):1309-1318.

［29］ Howarth FC, Adem A, Adeghate EA,et al. Distribution of atrial natriuretic peptide and its effects on contraction and intracellular calcium in ventricular myocytes from streptozotocininduced diabetic rat[J]. Peptides,2005,26(4):691-700.

［30］　Fukunaga Y, Itoh H, Doi K, et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides[J]. Atherosclerosis,2001,158(1):113-119.

［31］ Delerive P, MartinNizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein1 signaling pathway[J]. Circ Res, 1999,85(5):394-402.